Table 1 The clinical features between response and nonresponse groups in the HNSC patients
Features | Overall (n = 37) | Response (n = 29) | Nonresponse (n = 8) | p-value |
|---|---|---|---|---|
Gender (%) | Â | Â | Â | 1.000 |
 Male | 31 (83.8) | 24 (82.8) | 7 (87.5) |  |
 Female | 6 (16.2) | 5 (17.2) | 1 (12.5) |  |
Age (years) | Â | Â | Â | 0.941 |
 median | 57.0 | 57.0 | 56.5 |  |
 IQR | 50.0–64.0 | 49.0–64.0 | 53.8–63.8 |  |
Primary site (%) | Â | Â | Â | 0.631 |
 Oral cavity | 30 (81.1) | 24 (82.8) | 6 (75.0) |  |
 Oropharynx | 7 (18.9) | 5 (17.2) | 2 (25.0) |  |
HPV status (%) | ||||
 Negative | 7 (18.9) | 5 (17.2) | 2 (25.0) | NA |
 NA | 30 (81.1) | 24 (82.8) | 6 (75.0) |  |
p Stage (%) | Â | Â | Â | 1.000 |
 IVa | 26 (70.3) | 19 (65.5) | 7 (87.5) |  |
 IVb | 2 (5.4) | 2 (6.9) | 0 (0.0) |  |
 IVc | 6 (16.2) | 5 (17.2) | 1 (12.5) |  |
 NA | 3 (8.1) | 3 (10.3) | 0 (0.0) |  |
T stage (%) | Â | Â | Â | 0.099 |
 T1 | 1 (2.7) | 1 (3.4) | 0 (0.0) |  |
 T2 | 4 (10.8) | 2 (6.9) | 2 (25.0) |  |
 T4 | 19 (51.4) | 18 (62.1) | 1 (12.5) |  |
 NA | 13 (35.1) | 8 (27.6) | 5 (62.5) |  |
N stage (%) | Â | Â | Â | 0.664 |
 N1 | 3 (8.1) | 3 (10.3) | 0 (0.0) |  |
 N2 | 20 (54.1) | 13 (44.8) | 7 (87.5) |  |
 N3 | 1 (2.7) | 1 (3.4) | 0 (0.0) |  |
 NA | 13 (35.1) | 12 (41.4) | 1 (12.5) |  |
Tobacco (%) | Â | Â | Â | 0.670 |
 Yes | 13 (35.1) | 9 (31.0) | 4 (50.0) |  |
 No | 15 (40.5) | 12 (41.4) | 3 (37.5) |  |
 NA | 9 (24.3) | 8 (27.6) | 1 (12.5) |  |
Alcohol (%) | Â | Â | Â | 0.635 |
 Yes | 8 (21.6) | 5 (17.2) | 3 (37.5) |  |
 No | 18 (48.6) | 14 (48.3) | 4 (50.0) |  |
 NA | 11 (29.7) | 10 (34.5) | 1 (12.5) |  |